BR · Analyze — Financebot

Date: 2026-09-28 | Price: $162.87 (−0.59%) | Market cap: $18.57B | FY ends June 30 Baseline: analyze-2026-08-04.md — ACCUMULATE, conviction 8.5, at $168.41 Partial update since: health-2026-08-12.md at $169.27 Second-newest verdict file: analyze-2026-03-21.md at $174.36

1. What this updates

This pass exists to answer one question: does the $150–180 entry zone, set on 2026-08-04, survive a from-scratch re-derivation? On 2026-09-22 three of four in-zone held names lost their buy signal on contact with a refreshed fair value, and two live pitfalls ([[pitfall-stale-fair-value-is-most-costly-on-winners]], [[pitfall-stale-entry-zone-suppresses-a-name]]) say a two-month-old zone on the highest-conviction name in the book is exactly the dangerous case.

It found three things the baseline did not have, and two of them are material:

❌ A retraction. The baseline ran the equity-mark diagnostic, passed it, and was wrong. $2.00 of FY26's $9.60 GAAP EPS is a non-cash digital-asset mark.
🔄 The structural risk moved. The baseline called the proxy-fee risk "undated and perennial — a risk to underwrite, not a catalyst to trade." There are now two dated SEC proposals, one in an open comment period. They attack ICS volume, not the fee rate.
✅ The baseline's own open item resolved in its favour. The $1.5B buyback is executing.

On the central question: the zone does NOT survive intact. $150–180 → $148–166 — the top comes down 7.8%. $162.87 is still inside, but by 2%, not by a comfortable margin.

Event list since 2026-08-04

Date	Event	Touches	Grade
2026-08-03	8-K: dividend $0.975 → $1.09/qtr ($4.36/yr, +12%), 20th consecutive raise; $1.5B buyback authorized	Trend/State	Primary
2026-08-04	Q4 + FY26 results and FY27 guide (8-K Ex-99.1)	State	Primary
2026-08-04	Q4 call: "lower float income tied to interest rates + higher pass-through distribution revenue = 40bp margin headwind for the year"	Trend	Primary
2026-08-06	Morgan Stanley maintains Equal-Weight, PT $169 → $176	Price	Secondary
~2026-08	FY26 10-K on Reg E-Delivery (SEC proposed 2026-07-16): "no impact on financial results in fiscal year 2027," then "a modest decrease in recurring revenue growth over a two- to three-year period, largely offset with new solutions"	Regulatory	Primary
2026-08-24 wk	Price peaks $185.77, +10.3% off the baseline print	Price	Primary tape
2026-08-31	RBC Capital maintains Outperform, PT $225 → $226	Price	Secondary
2026-09-09	Broadridge launches DLX — end-to-end digital-asset infrastructure platform, built on DLR (>$350B/day)	Structural	Primary
2026-09-03 / 10-05	Dividend increase paid (record 9/3, pay 10/5)	Trend	Primary
2026-09-14	US wealth platform extended to crypto + tokenized securities; Anchorage Digital + Galaxy Digital for custody/liquidity	Structural	Primary
2026-09-16	SEC proposes rescission of Rule 14a-8 + proxy solicitation modernization. Eliminates the annual-report delivery requirement; broker search 20 → 5 business days; kills Notice of Exempt Solicitation. 60-day comment period from Federal Register publication.	Regulatory	Primary (SEC)
2026-09-16	FOMC +25bp to 3.75–4.00% — first hike since 2023; ~60% odds of another 10/28; 10yr ~4.96%	Price + Trend	Primary
2026-09-21	Insider Monkey: "Tokenized equities and AI disruption threaten BR's market share"	Narrative	Secondary
2026-09-23	Boaz Lahovitsky joins as President, Wealth Management, succeeding Mike Alexander	Structural	Primary
2026-08-04 → today	No 8-K guidance revision, no M&A, no litigation, no insider open-market trade	—	—

Events that touch nothing — reported per the command's instruction, because a loud quarter that hits no claim is itself a finding:

The 2026-09-25 Ondo/BlackRock tokenized-portfolio launch does not mention Broadridge. It moved BR's name around in crypto media with no BR involvement disclosed. Pure adjacency noise.
The 8/12 insider entries are RSU grants at $0.00, not purchases ([[pitfall-yahoo-insider-purchases-counts-rsu-grants]]).
The 9/21 bear piece recycles Fenimore's Q2 2026 investor letter, written before the 8/04 print, and its lead claim — an elongated sales cycle lowering 2026 sales — was contradicted by a record $158M Q4 and $305M full year with backlog up $40M to $470M. Sentiment artifact.
Both analyst actions were maintains with PT nudges of $7 and $1, both upward. No upgrade, no downgrade, no PT cut in eight weeks.

The structural observation: the window was loud — record Q4 sales, +12% dividend, $1.5B buyback, a whole tokenization product suite, a new division president — and almost none of it tests the central thesis claims. The two things that genuinely move it are the 9/16 SEC proposal (comment-period only, quantified by nobody) and the float-income reversal (written about by nobody).

2. The delta ledger

❌ RETRACTED — 2 rows. These are corrections to the record.

#	Baseline claim	What was wrong	Cause
St6	"✅ Diagnostic check: net margin 15% < operating margin 18%. No equity-mark distortion ([[pitfall-unrealized-equity-marks-break-headline-pe]] does not fire). Reported earnings are operating earnings."	There is a mark distortion and it is large. The company's own GAAP→adjusted bridge: `9.60 GAAP + 1.74 amortisation + 0.15 acquisition/integration + 0.11 restructuring − 1.94 digital-asset gains − 0.06 investment gain = 9.60 adjusted`. $2.00 per share — 20.8% of FY26 GAAP EPS — is a non-cash mark, of which $1.94 is a $227M gain on digital assets. FY25: nil.	Wrong test, not wrong data. The net-margin-below-operating-margin tripwire ([[pattern-net-margin-above-operating-margin-is-a-tripwire]]) only catches a mark large enough to invert the inequality. $227M against $1,300.6M of operating income and a 22.2% tax rate does not invert it — net margin 15.0% still sits below operating margin 17.4%. The test passed while the distortion was present, and was reported as conclusive. A reasoning error, not a vendor trap: the diagnostic was under-powered for its job.
T4	(health-2026-08-12) "Net income 3yr CAGR 21.3% on revenue 3yr CAGR 7.2%: margin expansion, not just growth."	Computed on mark-inflated FY26 net income. Clean FY26 net income ≈ $890M (clean EPS $7.60 × 117.1M diluted) → clean 3yr CAGR 12.2%, not 21.3%. And clean GAAP EPS growth is +7.0% ($7.10 → $7.60), not +35%.	Inherited directly from St6 — one error, two rows.

Corroboration — four independent sources, one of them primary.

A portfolio-specific passage was removed from the public build.

And the tax rate is clean. Pretax $1,445.8M − tax $321.6M = $1,124.3M net; effective rate 22.2%, UP from 20.7% (lower stock-comp excess benefits). The apparent "6% tax rate" that first flagged this is an artifact of computing operating income − interest expense as pretax and ignoring the gain. No discrete tax benefit, no asset sale, no vendor error.

What the retraction does NOT break — and this is the important half.

The mark is non-cash and is reversed out inside operating cash flow, so it never touched FCF. Everything the bull case actually rests on is uncontaminated:

Metric	Contaminated?	FY26
Free cash flow	No	$1,233M, +16.7% YoY
Operating cash flow	No	$1,345.6M
Operating income / margin	No	$1,300.6M / 17.40%
Gross margin	No	31.78%
Revenue	No	$7,476.8M, +8.6%
Adjusted EPS $9.60 (+12.3% vs FY25 $8.55)	No — the bridge strips the gain out explicitly	$9.60
FY27 guidance (built on adjusted)	No	+8–12%
GAAP diluted EPS $9.60	YES — $2.00/sh	clean $7.60
Trailing P/E 16.95×	YES	clean 21.4×
Net income & its 3yr CAGR	YES	clean $890M / 12.2%
EV/EBITDA 12.04× (Yahoo)	YES	clean 13.3× (roic.ai EBITDA)

The finding in one line: the cash case is intact and the GAAP earnings headline was flattered by a fifth. That is the least damaging shape this error could have taken, and it is why the verdict survives it while the conviction does not survive intact.

🔄 SUPERSEDED — 2 rows. One against the thesis, one for it.

#	Baseline claim	What replaced it	Cause
S4 ⬇	"A fee review is the one event that could reset ICS economics… What limits it: it is undated and perennial — fee reform has been 'recommended' before, and the process runs on a multi-year clock. It is a risk to underwrite, not a catalyst to trade." (and health-2026-08-12: "no dated action pending")	Both statements are now false. Two dated SEC proposals are live, and they attack ICS VOLUME rather than the fee RATE. (1) Reg E-Delivery, proposed 2026-07-16. (2) Rescission of Rule 14a-8 + proxy solicitation modernization, proposed 2026-09-16 — eliminates the annual-report delivery requirement, cuts the broker search from 20 → 5 business days, kills the Notice of Exempt Solicitation. 60-day comment period open. Every one of those items reduces the count of things BR gets paid per-position to distribute.	SEC rulemaking. The fee-rate risk itself has NOT moved — no NYSE fee filing, no Proxy Fee Advisory Committee action. The risk relocated, from an undated price risk to a dated volume risk.
T5 ⬆	"Share count has been flat (−0.1% CAGR over three years) — buybacks have mostly offset SBC rather than retiring stock… the one genuine criticism. Whether [the $1.5B] actually gets spent is the thing to watch, not the announcement."	It got spent. FY26 buybacks $603.7M — 4.5× the $134.9M of FY25. Shares outstanding 117.20M → 114.06M, −2.68%; diluted average 118.3M → 117.1M. Funded with zero net new debt ($2,017.0M issued against $2,015.6M repaid).	The FY26 cash-flow statement, unavailable on 8/04. This was the highest-priority open item the baseline handed forward, and it resolved in the thesis's favour.

On S4 — how bad is it, actually? BR's own FY26 10-K quantifies the E-Delivery exposure and the answer is not catastrophic: "no impact on financial results in fiscal year 2027," then "a modest decrease in recurring revenue growth over a two- to three-year period, largely offset with new solutions," plus a decline in distribution revenue which — because distribution is low-margin pass-through — raises margin. But that statement is about Reg E-Delivery only. Nobody, company or sell-side, has quantified the 2026-09-16 proposal. Do not conflate the two. Nothing is adopted and nothing is effective; a comment period is the earliest possible stage.

FY26 capital allocation of $1,233M of FCF: dividends $443.5M (36%) + buybacks $603.7M (49%) + acquisitions $282.7M (23%) = 108% of FCF, the excess drawn from cash ($561.5M → $402.9M) rather than from the balance sheet. An aggressive, fully-funded return year.

📉 DRIFTED — 3 rows

#	Claim	Drift	Breaks at
T2	"Operating margin expanded 400bps in three years (13.3% → 17.3%)"	FY26 landed at 17.40% — +15bp, against +162bp in FY25. The expansion engine stalled. But it has a named, non-structural cause, from management on the Q4 call: "lower float income tied to interest rates + higher pass-through distribution revenue = a 40bp margin headwind for the year." Both are reversing: the Fed hiked on 9/16, and E-Delivery shrinks pass-through distribution. FY27 is guided to ~21% adjusted operating margin, up, with $25M of AI-driven productivity gains funding reinvestment.	Operating margin below 17.0% for a full year, or FY27 adjusted operating margin coming in below 20.5% against the ~21% guide. That would mean the stall was structural after all.
P6	"DYT: 2.59% vs 1.64% 5yr avg… roughly two-thirds of it is the price."	Upgrade the caution: the comparator is broken, not merely diluted. The 5yr window spans a period when BR traded at 25–30× on a multiple the market has permanently reset. Naively, $4.36 ÷ 1.69% implies a "fair" price of $258 — above the 52-week high. The yield band is not a stationary series for this name. DYT is void for BR and is excluded from the weighted average.	n/a — retire the model. See [[pitfall-dyt-inverts-when-price-caused-the-yield]] and [[pattern-cheapness-signals-that-are-all-artifacts]].
P8	"−38.1% off its 52-week high of $271.91"	The 52-week window rolled: the high is now $238.73, so the same price is −31.8% off. A drawdown-based cheapness anchor weakened ~6pts with no trade occurring.	n/a — an anchor to stop quoting.

🔁 REFRESHED — 8 rows

#	Claim	Old → New
T3	FCF CAGR	"41.8% over three years" → 18.1% (FY23 $748.1M → FY26 $1,233M). The 41.8% was a base effect off a depressed FY22 ($370M); the 8/12 health file had already corrected it. FCF +16.7% YoY, 91% conversion, capex 1.51% of revenue. Still the best cash-conversion record on the watchlist — just not at 42%.
T6	Debt	$3.46B → $3.52B (+$60M, acquisition-related). But interest expense $135.8M → $111.8M (−17.7%), coverage 8.8× → 11.6×, net debt / clean EBITDA 1.90×, zero net issuance. The near-term maturity was already cleared before the hike: 2026-05-06, $500M of 5.750% senior notes due 2036 issued to repay the 3.400% notes due 2026 — a ~235bp coupon step-up, taken voluntarily and early.
T7	Dividend	20th consecutive raise paid — record 9/3, pay 10/5, $0.975 → $1.09/qtr = $4.36/yr. FCF payout 36.0%. 10yr dividend CAGR ≈12.6%, 8yr ≈11.7%.
St1	FY26 results	Revenue $7,476.8M +8.6% · recurring ~$4.9B +8% cc · adjusted EPS $9.60, +12.3% (FY25 $8.55) · closed sales $305M with a record $158M Q4 · backlog $470M, +$40M (new disclosure the baseline did not carry).
St2	FY27 guide	Recurring +6–8% cc · adjusted EPS +8–12% ($10.37–10.75, mid $10.56) → now with three fields the baseline omitted: adjusted operating margin ~21%, FCF conversion >100%, closed sales $290–330M. No revision, no 8-K, no pre-announcement in eight weeks.
St3	$1.5B authorization	See SUPERSEDED T5 — executing. ⚠️ FY27 execution is not yet disclosed; the Q1 FY27 10-Q is the first read.
St4	Debt/assets	40.5% → 39.32%
St8	Yield / payout	2.59% / 41% GAAP → 2.68% / 36% FCF

✅ CARRIED — 7 rows

#	Claim	The check
S1	80–90%+ of North American proxy communications; regulated-monopoly-adjacent infrastructure; 7bn+ communications/yr	No competitor entry, no mandate rescinded. Survived three consecutive re-tests (Mar, Aug, now). Note the 9/16 proposal trims what must be delivered, not who delivers it.
S3	ICS ~65% / GTO ~35%	No segment reclassification, no disposal.
S5	Tokenization is a tailwind, not a threat	Strengthened, on primary sources: DLX launched 9/09 (end-to-end tokenized-market infrastructure on DLR, >$350B/day); the US wealth platform extended to crypto and tokenized securities 9/14 with Anchorage and Galaxy. ⚠️ Zero dollars are attached in any primary source — the FY27 6–8% cc guide does not appear to carry tokenization revenue. Narrative, not model.
S7	Evergreen 8.5/10	Held. Regulatory dependency remains the ceiling — and it just got more concrete.
S8	Capex ~1.7% of revenue, no capex cliff	FY26: $112.6M / $7,476.8M = 1.51%.
T1	Revenue growth accelerating 6.1 → 7.4 → 5.8 → 8.6%	Confirmed on the full FY26 statement.
St5	FY26 FCF $1.23B, OCF $1.35B, 91% conversion, FCF/sh $10.53	Re-derived from the statement; exact.

🆕 NEW — 7 rows

#	Finding
N1	Broadridge now carries digital assets marked to market, so GAAP EPS has a crypto-price beta. That is what produced the $227M FY26 gain, and it already turned: Q4 FY26 alone carried an $11M digital-asset loss. This is a genuine new structural fact about the company — a financial-infrastructure business took a balance-sheet position in a volatile asset — and it means FY27 GAAP comparisons will look bad against an inflated FY26 base for reasons unrelated to operations. ⚠️ The composition and carrying value of those assets could not be verified — the 10-K note was not reached. The thinnest part of this report.
N2	Vendor forward P/E is the wrong fiscal year. Yahoo prints 14.05×, implying forward EPS of $11.59 — 7.8% above the top of the FY27 guide. That is FY28. True forward P/E on the guided FY27 midpoint of $10.56 is 15.4×. [[pitfall-vendor-forward-eps-is-the-wrong-fiscal-year]] fires.
N3	…which makes the multiple-trim render ~10% high. `site.py` computes the trim dollar as `multiple × (price ÷ vendor forwardPE)`. At 20× that renders 20 × $11.59 = $232 instead of the intended 20 × $10.56 = $211. [[pitfall-multiple-trim-inherits-the-broken-vendor-field]] fires live. The `ttm` basis is far worse (implied $9.61 vs clean $7.60, +26%), so `fwd` stays the lesser evil. Flagged, not silently re-based.
N4	The rate hike is a TAILWIND to BR's margin, and nobody has written about it. Management named lower float income as part of a 40bp FY26 margin headwind; a rising path reverses that line. On the funding side BR pre-cleared its near-term maturity in May 2026 ($500M at 5.750% due 2036), interest expense has fallen 26% across the cycle ($150.2M → $135.8M → $111.8M), coverage is 11.6×, and it added zero net debt in FY26. Floating exposure is the revolver and term loans at SOFR + 100bp. ⚠️ The full maturity ladder, the fixed/floating split, the client-float balance and Item 7A rate sensitivity were NOT verified. The Fed damages what I will pay for BR; on the evidence available it helps what BR earns.
N5	Moat quantitative base, computed rather than asserted. The baseline asserted the moat without ever running ROIC. Clean NOPAT ÷ invested capital: 14.7% (FY24) → 15.9% (FY25) → 16.6% (FY26). Gross margin 29.7% → 31.0% → 31.8%. Both rising through the de-rating. (On Yahoo's contaminated EBIT this reads 19.9% — overstated 330bp.)
N6	Insider, absent from the baseline. CEO Timothy Gokey made a $1.03M open-market purchase — 5,300 shares at $194.49 on 2026-03-06, 19% above today's price. Zero insider open-market trades of any kind since 2026-06-04. The contrast with 2025 is the signal: management sold heavily into $230–262 and the CEO bought the decline.
N7	The baseline's price call ran, then fully reversed. $168.41 (8/04) → $185.77 peak (wk of 8/24, +10.3%) → $162.87. A 4th instance of [[pattern-shortlist-runs-when-unexecuted]] — and the first where the run round-tripped entirely, which is new information about that pattern.

⏳ UNTESTED — 3 rows

#	Claim	Why
S2	Revenue retention 98%	No disclosure since 8/04. Second consecutive pass untested — flagged per the command's standing rule. The system keeps deferring this question. Resolves at the Q1 FY27 print.
S6	"Digitization compresses per-piece distribution economics as fast as it compresses the cost line"	Asserted in the baseline, never evidenced, not evidenced here — it needs ICS segment margin at a granularity BR does not publish. ⚠️ It is now the load-bearing assumption under the whole E-Delivery response, because BR's "largely offset, and margin rises" claim is this claim. Promoted from a footnote to the most important untested row in the file.
J-new	Effect of the 2026-09-16 SEC proposal on ICS revenue	Quantified by nobody — not the company, not the sell-side, not the press. BR's "no FY27 impact / modest over 2–3 years" line is about Reg E-Delivery only.

3. How the close calls were decided

(a) Does the retraction break the thesis, or only the headline? Against: GAAP EPS overstated 26%, trailing P/E understated by a fifth, net-income CAGR overstated 9pts, and — worst — the baseline's reasoning was wrong, not just its data. For: the mark is non-cash and reversed out in operating cash flow, so FCF, OCF, operating income, gross margin, revenue and adjusted EPS are untouched; the company's own bridge strips the gain explicitly; and adjusted EPS is what the FY27 guide is built on. Decision: the thesis survives, the conviction does not survive intact. The verdict was never carried by GAAP net income — it was carried by FCF and the guide. But the command's own rule — "conviction should reflect the volatility of your own analysis" — costs this pass 0.3, because a diagnostic was reported as conclusive when it was under-powered for its job.

(b) The hardest call: does the SEC proposal break the moat or only tax it? For a break: the baseline's own framing conceded that regulation, not competition, is the mechanism that can reset ICS economics — and regulation just acted twice in ten weeks. Eliminating the annual-report delivery mandate and cutting the broker search from 20 to 5 business days directly reduces the count of paid-for distributions. Against a break: neither proposal touches who delivers — BR's plumbing monopoly is untouched; both are at the earliest possible procedural stage with nothing adopted; BR's own 10-K quantifies the E-Delivery half as "modest… largely offset," and because distribution revenue is low-margin pass-through, shrinking it raises margin. Decision: SUPERSEDED, not a thesis break. The risk's character changed — undated price risk → dated volume risk — and that is a real conviction cost (−0.4) because the baseline explicitly rested on it being undated. But the S1 moat row carries untouched, and a comment period is not an outcome.

(c) Does the FY26 margin stall (T2) accumulate into a Structural break? This looked like the central Structural-vs-State call until management's own words resolved it. For a break: ICS is a regulated-price business facing digitization; a stalled margin is the first symptom. Against: gross margin rose 80bp in the same year and ROIC rose 70bp — genuine moat erosion shows up in gross margin first, and gross margin went the other way. And the cause is named and cyclical: float income and pass-through mix, worth 40bp, from the Q4 call. Both components are now reversing, and FY27 is guided to ~21% adjusted operating margin. Decision: DRIFTED, with a named break level (FY27 adjusted operating margin <20.5%) so the next pass has a number.

(d) Do the tokenization headlines change anything? DLX (9/09) and the wealth-platform extension (9/14) are real primary-source product launches and they strengthen S5. But no economics are disclosed anywhere, and the FY27 guide does not appear to carry tokenization revenue. Per the command's instruction that "the AI narrative shifted" is a Price force in a Structural costume, the 9/21 bear piece and the 9/25 Ondo story were both logged against Price. Neither described a business-model change. And the 9/25 story does not mention Broadridge at all.

(e) Fair value: how much is the Fed, how much is the SEC, and how much is me? Per [[pitfall-stale-fair-value-is-most-costly-on-winners]] rule 3 — change the inputs before changing the assumptions, and report both separately.

Step	FV centre	Driver
Baseline 8/04	$211	20× FY27 $10.56
Inputs only (guide unchanged, shares −2.7%, FCF +16.7%, backlog +$40M)	$213	the business, slightly better
Assumption: discount rate +70bp	$200	the Fed
Assumption: terminal growth 3.5% → 3.0% on dated volume risk	$195	the SEC

The business contributed +1%. The Fed took 6%. The SEC took 2.5%. None of the cut is a change of opinion about Broadridge, and that decomposition is why this ends as a zone narrowing rather than a verdict change.

4. Thesis persistence and conviction delta

Structural + Trend rows: 16 → 11 CARRIED or REFRESHED = 69% persistence. The five that moved: one RETRACTED (T4, downstream of a single reasoning error), one SUPERSEDED against (S4, the regulatory character change), one SUPERSEDED for (T5, the buyback), one DRIFTED with a named reversing cause (T2), one UNTESTED-twice (S2).

69% persistence against a −3.3% price move since baseline and −12.3% off the 8/24 peak. The business held. What changed is the discount rate and the shape of a risk that was always on the page.

Conviction: 8.5 → 7.5

Direction	Row	Weight
➖	S4 SUPERSEDED — "undated and perennial, a risk to underwrite not a catalyst to trade" is no longer true. Two dated SEC proposals, one in an open comment period, both on ICS volume. Nobody has quantified the 9/16 one.	−0.4
➖	St6 RETRACTED — the mark diagnostic was run, passed, and was wrong. Analysis-quality cost, not business cost.	−0.3
➖	P1 fair value −7.6% on a +70bp risk-free (~60% odds of another hike 10/28) and a lower terminal growth rate.	−0.4
➖	N1 + T4 — clean trailing P/E is 21.4×, not 16.95×; clean net-income CAGR 12.2%, not 21.3%; and GAAP EPS now carries crypto beta. The trailing multiple is not cheap.	−0.3
➕	T5 SUPERSEDED for — the buyback is real: $603.7M, 4.5× prior year, shares −2.7%, zero net debt. The baseline's single stated reservation, answered with cash.	+0.3
➕	T2 + N4 — the margin stall has a named, cyclical, self-reversing cause (float income), FY27 guides margin up to ~21% with $25M of AI productivity, and the Fed hike helps that line.	+0.3
➕	N5 + N6 + St1 — ROIC and gross margin both rising through the de-rating; CEO bought $1.03M at $194.49 with no insider selling since June; backlog +$40M on a record Q4.	+0.1
	Net	−0.7 → 7.5

At [7.5] BR is no longer the top conviction on the file, and this pass should not pretend to know what is — that belongs to /watchlist-scan, not to a single-name run.

5. Updated valuation — re-derived from scratch

Forward EPS is taken from management's guide, not from a vendor field (see N2). FY26 adjusted EPS $9.60 × (1 + 8–12%) = $10.37–10.75, midpoint $10.56.

Model	Input	Result	Weight
Forward P/E	$162.87 ÷ $10.56	15.4× (not Yahoo's 14.05×)	—
FCF yield / reverse-DCF	FCF $1,233M ÷ $18.57B = 6.64%; r = 4.96% + 0.91 × 4.5% = 9.05%	terminal g 2.5% → $169 · 3.0% → $184 · 3.5% → $202	Highest — uncontaminated
Bogle expected return	2.68% yield + 10.0% guided adjusted-EPS growth	12.7%/yr with no re-rating	High
Trailing P/E	$162.87 ÷ clean GAAP $7.60	21.4× (headline 16.95× is mark-flattered)	Context
EV/EBITDA	$21.79B ÷ clean $1,641.9M	13.3× (headline 12.04× is contaminated)	Context
Graham IV	√(22.5 × 7.60 × 24.92)	$65 — void, not a floor	Zero
DDM	D₁ $4.80, r 9.5%, g 7–8%	$192–$320	Very low
DYT	2.68% vs 1.69% 5yr avg → implies $258	VOID	Zero
Consensus	mean ~$215 (18 analysts, ~79% buy) · RBC $226 · Morgan Stanley $176	+32%	Context

Two models are struck this pass. Graham is void because BR carries $3.79B of goodwill against $2.84B of equity — tangible book is negative $0.95B, so √(22.5 × EPS × BVPS) computes a liquidation anchor on an asset that would not survive liquidation. DYT is void per DRIFTED row P6. Neither belongs in a weighted average and neither is in one.

Bogle is still the load-bearing model, and it is the one the retraction did not touch: the current yield plus the midpoint of management's own adjusted-EPS guide returns 12.7% annually with no multiple re-rating at all. Against a 4.96% 10yr that is a ~7.7pt spread — narrower than in August, when the same calculation faced a lower risk-free, but still the core of the case.

Fair value: $175–215, central $195 (= 16.6–20.4× FY27 adjusted EPS of $10.56)

Down from $190–230 / $211, −7.6% at the midpoint. Per §3e: the Fed took 6%, the SEC took 2.5%, the business gave back +1%. The band stays deliberately below the 25–30× BR commanded historically; no return to the old band is modelled.

At $162.87 the stock is 16.5% below central fair value and 7.0% below the band floor.

Zones

	Baseline 8/04	Now	Why
Fair value	$190–230 (c. $211)	$175–215 (c. $195)	discount rate +70bp; terminal growth 3.5% → 3.0% on dated volume risk
Entry	$150–180	$148–166	the top must keep the baseline's own ~14% margin below centre; $180 is now 7.7% above the new centre — it would be buying above fair value. $148 holds as the floor: where the FCF yield reaches 7.3%.
Trim	22× fwd	20× fwd	= the top of the fair-value band, the baseline's own convention; it falls for the same reasons the band fell. 20 × $10.56 = $211, +29.6% from spot.

⚠️ Does the $150–180 zone survive? No — not intact. And the margin is now thin.

The top comes down $180 → $166, a 7.8% cut. The floor moves $150 → $148.

$162.87 is still inside the re-derived zone — but by 2.0%, not by the comfortable ~10% the baseline implied. BR went from "in zone, ~25% below centre" to "just inside the top of a narrower zone, 16.5% below a lower centre." The buy signal survives; the comfort does not.

Where this sits against 2026-09-22. Three of four in-zone held names lost their signal that day. BR keeps its, narrowly — so the 9/22 result was a finding about those four names, not a law. But the reason BR survives is specific and worth recording: its staleness was in the fair value, not the price. The price fell 3.3% since the zone was set while the fair value fell 7.6% — they moved the same direction, so the gap only partly closed. The 9/22 failures were names whose price ran away from a static ceiling. A stale zone on a flat stock is the mild case. This is what the mild case looks like, and it still cost 14 dollars off the top of the zone.

A 4% further decline in the stock, or a single adverse SEC development, puts BR out of zone.

6. Verdict — 🟢 ACCUMULATE · conviction [7.5] (from 8.5) ·

What still carries it:

The cash is real and compounding, and the retraction does not touch it. FCF $1,233M, +16.7%, 18.1% 3yr CAGR, 91% conversion, capex 1.51% of revenue, 36% FCF payout, FY27 guided to >100% conversion. The $227M mark is non-cash and reversed out inside operating cash flow.
The baseline's stated reservation was answered with cash, not words. $603.7M of buybacks (4.5× prior year), shares −2.7%, zero net new debt. "Whether it actually gets spent is the thing to watch" — it was spent.
The moat is measurable and improving. ROIC 14.7 → 15.9 → 16.6%, gross margin 29.7 → 31.0 → 31.8%, both rising through a 32% de-rating, on a legally mandated workflow.
The Fed hit the multiple and helps the business. Float income is a named FY26 headwind now reversing; the near-term maturity was pre-cleared in May; interest expense −17.7%; coverage 11.6×.
Bogle still returns 12.7%/yr with no re-rating, on management's own guide.

Why not [8.5] any more — three separate reasons, and they are independent:

The structural risk changed character: from undated and perennial to two dated SEC proposals on ICS volume, one in an open comment period, quantified by nobody.
The analysis retracted its own earnings-quality clearance. Clean trailing P/E is 21.4×, not 17×, and GAAP EPS now carries a crypto mark that already reversed $11M in Q4.
Fair value fell 7.6% on a risk-free that may rise again on 10/28.

Why not lower: every claim that actually carries the verdict — FCF, the guide, retention, ROIC, the dividend, the buyback, the backlog — came back CARRIED, REFRESHED or SUPERSEDED-in-favour. 69% thesis persistence, and Morgan Stanley's $176 — the honest bear target — is still above spot.

Break triggers - Any SEC advance on the 2026-09-16 proposal or Reg E-Delivery beyond comment — adoption, a re-proposal, or a quantified company estimate. This has displaced the fee review as the live regulatory risk. (Comment period closes ~Nov–Dec 2026, 60 days from Federal Register publication — the exact date is not yet confirmed.) - NYSE/SEC action on proxy distribution FEES — still the larger, still-undated risk. Unmoved. - FY27 adjusted operating margin guided or tracking below 20.5% against the ~21% guide — it would mean the FY26 stall was structural, not float income. - Closed sales down two consecutive quarters, or recurring revenue growth below 6% cc. - FY27 buybacks below ~$300M — it would re-open the criticism the FY26 print just closed. - Dividend streak broken (would be the 21st year). - ⚠️ Do not misread the FY27 GAAP compare. It will look bad against a mark-inflated FY26 base for reasons unrelated to operations — and do not let a fresh mark in the other direction flatter it. Use adjusted EPS and FCF for this name until the digital-asset position is understood.

Upgrade back toward [8.0+]: the 9/16 proposal quantified by the company at a modest number, or withdrawn · ICS segment margin disclosed and holding (resolves S6 and T2 together) · FY27 tracking to the upper half of the 8–12% guide with the buyback at FY26 pace · the digital-asset position sized and disclosed.